

DUAL THERAPY WITH CAROTEGRAST (AJM300: ORAL A4 INTEGRIN ANTAGONIST) AND BIOLOGICS FOR REFRACTORY ULCERATIVE COLITIS

Eiko Saito

UEG Week Copenhagen 2023

Poster

IBD

October 15, 2023

A small case series from Tokyo Medical and Dental University examined dual therapy combining carotegrast with other biologics in six patients with treatment-refractory ulcerative colitis.

KEY POINTS

- All five patients who continued treatment achieved pMayo score of 0 at 2 weeks and maintained it through 6-8 weeks, then transitioned to biologic maintenance therapy.
- The six patients had median pMayo score of 5.0 at baseline, with half being steroid-refractory and half steroid-dependent, and all had prior inadequate response or loss of response to biologics.
- Carotegrast was combined with ustekinumab in four cases and infliximab in two cases, with median 14.5 days between last biologic dose and carotegrast initiation.
- One patient discontinued carotegrast due to epigastric pain; no other side effects were observed during mean 38.8 days of carotegrast administration.
- The authors conclude dual therapy may be effective and safe in biologics-failure ulcerative colitis, though this reflects a very small sample with short-term follow-up.

VIEW THIS CONTENT ON GUTFLIX

<https://gutflix.eu/search/d/9e9b4ec2-743c-11ee-b951-0242ac140004>



AI-generated summary

This summary was generated by an AI large language model based on the content transcript. It is for informational purposes only and should not be considered a substitute for clinical judgment. Always rely on your professional expertise and the full clinical context when making clinical decisions.